The purpose of this research was ..." /> <P>猕猴皮下注射重组人甲状旁腺激素的药代动力学研究</P>
http://jcps.bjmu.edu.cn

• 研究论文 • 上一篇    下一篇

猕猴皮下注射重组人甲状旁腺激素的药代动力学研究

宋雪伟, 陈知航, 车津晶, 单成启, 侯禹男, 郑仁玖, 程远国*   

  1. 1.军事医学科学院 微生物流行病研究所 药物代谢动力学研究室, 北京 100071; 2.吉林省长白山科学研究院, 吉林 133613
  • 收稿日期:2007-11-23 修回日期:2008-05-10 出版日期:2008-06-15 发布日期:2008-06-15
  • 通讯作者: 程远国*

Pharmacokinetics of recombinant human parathyroid hormone after subcutaneous administration in Rhesus monkeys by immunoradiometric assay

Xue-Wei Song, Zhi-Hang Chen, Jin-Jing Che, Cheng-Qi Shan, Yu-Nan Hou,
Ren-Jiu Zheng, Yuan-Guo Cheng*   

  1. 1. Laboratory of Drug Metabolism and Pharmacokinetics, Institute of Microbiology and Epidemiology, Academy of
    Military Medical Sciences, Beijing 100071, China; 2. Scientific Institute of Changbaishan, Jilin 133613, China
  • Received:2007-11-23 Revised:2008-05-10 Online:2008-06-15 Published:2008-06-15
  • Contact: Yuan-Guo Cheng*

摘要:

研究猕猴皮下注射重组人甲状旁腺激素[rhPTH (1-34)]后的药代动力学及生物利用度。猕猴皮下注射rhPTH (1-34) 10, 20 40 μg/kg, 静脉注射rhPTH (1-34) 20 μg/kg以及连续皮下注射rhPTH (1-34) 40 μg/kg (每天一次, 连续14), 应用放免方法 (IRMA)检测血浆样本中药物浓度, 然后采用非房室模型计算药代动力学参数。IRMA方法检测血浆中rhPTH (1-34)的线性范围 0.027 - 2.22 ng/mL。日内和日间精密度都小于15%, 并且平均回收率约为93.0% ± 8.6% ~ 116.5% ± 14.0%。猕猴皮下注 rhPTH (1-34) 10, 20 40 μg/kg, 平均达峰时间Tmax分别为0.67, 0.50.83 h, 峰浓度Cmax分别为1.85 ± 0.05, 3.23 ± 0.25 7.15 ± 1.19 ng/mL, 曲线下面积AUC(0-∞)分别为3.4 ± 0.6, 10.7 ± 1.3 12.6 ± 1.5 ng/h/mL, 末端相消除半衰期T1/2分别为0.72 ± 0.10, 1.15 ± 0.10 1.03 ± 0.06 h。猕猴皮下注射rhPTH (1-34) 20 μg/kg的绝对生物利用度为46.96%。连续注射猕猴rhPTH (1-34)后无药物蓄 积。IRMA方法具有高灵敏度及专属性, 适用于猕猴皮下注射rhPTH (1-34)后的药物药代动力学研究。在给予剂量范围内, 猕猴 体内的rhPTH (1-34)药物代谢符合线性动力学特征。

关键词: 重组人甲状旁腺激素, 重组人甲状旁腺激素, 重组人甲状旁腺激素, 药代动力学, 药代动力学, 药代动力学, IRMA, IRMA, IRMA, 生物利用度, 生物利用度, 生物利用度, 猕猴, 猕猴, 猕猴, , ,

Abstract:

The purpose of this research was to study the pharmacokinetics and the bioavailability of recombinant human parathyroid hormone [rhPTH (1-34)] in Rhesus monkeys after single and multiple subcutaneous administration. An immunoradiometric assay (IRMA) was used to determine the plasma drug concentration of rhPTH (1-34) after giving single dose of 10, 20 and 40 μg/kg and daily dose of 40 μg/kg for 7 d by subcutaneous administration, and intravenous injection of 20 μg/kg in Rhesus monkeys. The pharmacokinetic parameters were calculated by noncompartmental analysis. The drug plasma level quantitation range was from 0.027 to 2.22 ng/mL. The intra- and inter-assay precision (CV) of analysis were less than 15%, and the average recovery was about 93.0% ± 8.6% - 116.5% ± 14.0%. After subcutaneous administration of rhPTH(1-34) at dose of 10, 20 and 40 μg/kg, the average Tmax was 0.67, 0.5 and 0.83 h, Cmax were 1.85 ± 0.05, 3.23 ± 0.25 and 7.15 ± 1.19 ng/mL, the AUC(0-∞) were 3.4 ± 0.6, 10.7 ± 1.3 and 12.6 ± 1.5 ng/h/mL, and terminal-phase elimination T1/2 were 0.72 ± 0.10, 1.15 ± 0.10 and 1.03 ± 0.06 h, respectively. The absolute bioavailability of rhPTH (1-34) was 46.96% after subcutaneous administration of 20 μg/kg. There was no evidence of accumulation during systemic exposure of rhPTH (1-34) upon multiple dosing in Rhesus monkeys. The IRMA assay method provide reasonable sensitivity and specificity for the pharmacokinetic study of rhPTH (1-34) after subcutaneous or intravenous administration in Rhesus monkeys. The pharmacokinetic characteristic of rhPTH (1-34) in monkeys shows linear relationship with the dose administered subcutaneously.

Key words: RhPTH (1-34), RhPTH (1-34), Pharmacokinetic, Pharmacokinetic, IRMA, IRMA, Bioavailability, Bioavailability, Rhesus monkey, Rhesus monkey, ,

中图分类号: 

Supporting: We gratefully acknowledge the dedicated staff of our laboratory of drug metabolism and pharmacokinetics for their assistance and direction during the trial.